Wall Street brokerages expect UroGen Pharma Ltd. (NASDAQ:URGN) to announce $17.20 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for UroGen Pharma’s earnings, with the highest sales estimate coming in at $17.90 million and the lowest estimate coming in at $16.50 million. UroGen Pharma posted sales of $7.97 million in the same quarter last year, which suggests a positive year over year growth rate of 115.8%. The firm is expected to report its next quarterly earnings report on Thursday, March 17th.
On average, analysts expect that UroGen Pharma will report full year sales of $47.60 million for the current financial year, with estimates ranging from $46.90 million to $48.30 million. For the next financial year, analysts expect that the business will report sales of $108.23 million, with estimates ranging from $104.10 million to $114.50 million. Zacks’ sales averages are an average based on a survey of analysts that cover UroGen Pharma.
UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Monday, November 15th. The company reported ($1.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.26) by ($0.09). The business had revenue of $11.35 million for the quarter, compared to the consensus estimate of $15.90 million. UroGen Pharma had a negative return on equity of 173.25% and a negative net margin of 283.41%. During the same quarter last year, the company earned ($1.31) earnings per share.
In other news, CFO Molly Henderson sold 2,587 shares of UroGen Pharma stock in a transaction that occurred on Tuesday, November 30th. The shares were sold at an average price of $12.03, for a total value of $31,121.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Elizabeth A. Barrett sold 46,968 shares of the business’s stock in a transaction that occurred on Tuesday, January 4th. The shares were sold at an average price of $9.15, for a total transaction of $429,757.20. The disclosure for this sale can be found here. Insiders sold a total of 53,723 shares of company stock worth $512,802 in the last three months. Company insiders own 12.80% of the company’s stock.
Several institutional investors have recently modified their holdings of URGN. RTW Investments LP bought a new stake in shares of UroGen Pharma in the third quarter worth $14,423,000. Great Point Partners LLC bought a new position in shares of UroGen Pharma during the 3rd quarter worth about $12,615,000. Zeke Capital Advisors LLC boosted its position in shares of UroGen Pharma by 39.8% during the 2nd quarter. Zeke Capital Advisors LLC now owns 722,875 shares of the company’s stock worth $11,038,000 after purchasing an additional 205,769 shares in the last quarter. HealthInvest Partners AB bought a new position in shares of UroGen Pharma during the 3rd quarter worth about $1,262,000. Finally, Morgan Stanley raised its holdings in shares of UroGen Pharma by 5,869.2% in the 2nd quarter. Morgan Stanley now owns 73,600 shares of the company’s stock worth $1,125,000 after acquiring an additional 72,367 shares during the last quarter.
Shares of NASDAQ:URGN traded up $0.14 during midday trading on Friday, hitting $8.49. The company had a trading volume of 95,456 shares, compared to its average volume of 137,296. UroGen Pharma has a 12 month low of $8.06 and a 12 month high of $28.20. The firm has a fifty day simple moving average of $11.59 and a 200 day simple moving average of $14.58.
UroGen Pharma Company Profile
UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.
Featured Story: Stock Market News Sentiment
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.